Sorrento Therapeutics, Inc. is a biopharmaceutical company, active in both clinical development and commercial operations, dedicated to creating treatments for a range of serious conditions including cancer, autoimmune disorders, inflammatory diseases, viral infections, and neurodegenerative ailments. The company's operations are divided into two distinct segments: Sorrento Therapeutics and Scilex. A core focus lies in cancer therapeutics, where Sorrento harnesses its proprietary G-MAB antibody library. This is complemented by advanced, targeted delivery systems such as chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, antibody-drug conjugates, and innovative bispecific antibody approaches. Additionally, their Sofusa drug delivery technology offers a unique method for introducing biologics directly into the lymphatic system. Sorrento's clinical pipeline features several promising candidates. These include an anti-CD38 CAR-T therapy currently being developed for multiple myeloma, amyloidosis, and graft-versus-host disease. They are also advancing resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin, for managing late-stage cancer pain and osteoarthritis knee pain. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. Other significant developments comprise SEMDEXA, an injectable viscous gel in Phase III trials for sciatica, a specific form of low back pain; SP-103, an investigational non-aqueous lidocaine topical system targeting chronic low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for fibromyalgia treatment. The company actively engages in strategic collaborations, including partnerships with SmartPharm Therapeutics Inc. to develop a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical study involving up to 94 COVID-19 patients. Sorrento also works with the Mount Sinai Health System on COVI-SHIELD, an antibody therapy designed to combat SARS-CoV-2 infection, and with the Mayo Clinic on a Phase Ib pilot study utilizing the Sofusa lymphatic drug delivery technology for Ipilimumab in melanoma patients. Established in 2006, Sorrento Therapeutics, Inc. is headquartered in San Diego, California.